A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.

See also
Status	Clinical Trial	Phase
Completed	`NCT01432223` - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab	Phase 2
Completed	`NCT01305941` - A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases	Phase 2
Completed	`NCT01433926` - Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years	N/A
Recruiting	`NCT05871918` - A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer	Phase 3
Terminated	`NCT02598310` - Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT02568839` - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer	Phase 2/Phase 3
Terminated	`NCT02154529` - Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT01565200` - HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1	Phase 2
Completed	`NCT01340430` - Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT02947685` - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer	Phase 3
Completed	`NCT02066532` - Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	Phase 1/Phase 2
Completed	`NCT01583426` - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)	Phase 3
Completed	`NCT01677455` - An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer	Phase 2
Withdrawn	`NCT01361945` - AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT02326974` - T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA	Phase 2
Not yet recruiting	`NCT04644406` - PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Terminated	`NCT02131506` - A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer	Phase 1
Completed	`NCT00788931` - A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer	Phase 1
Completed	`NCT02488564` - A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer	Phase 2
Completed	`NCT02492711` - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	Phase 3

NCT number	NCT02675231
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	May 23, 2016
Completion date	November 9, 2023

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer — monarcHER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms